Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Levofloxacin Anhydrous. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 8/20 | 1.00 |
| ▸ | TUBB4A | P04350 | 7/20 | 1.00 |
| ▸ | TUBB | P07437 | 7/20 | 1.00 |
| ▸ | TUBA3C | P0DPH7 | 7/20 | 1.00 |
| ▸ | TUBA1B | P68363 | 7/20 | 1.00 |
| ▸ | TUBA4A | P68366 | 7/20 | 1.00 |
| ▸ | TUBB4B | P68371 | 7/20 | 1.00 |
| ▸ | TUBB3 | Q13509 | 7/20 | 1.00 |
| ▸ | TUBB2A | Q13885 | 7/20 | 1.00 |
| ▸ | TUBB8 | Q3ZCM7 | 7/20 | 1.00 |
| ▸ | TUBA3E | Q6PEY2 | 7/20 | 1.00 |
| ▸ | TUBA1A | Q71U36 | 7/20 | 1.00 |
| ▸ | TUBA1C | Q9BQE3 | 7/20 | 1.00 |
| ▸ | TUBB6 | Q9BUF5 | 7/20 | 1.00 |
| ▸ | TUBB2B | Q9BVA1 | 7/20 | 1.00 |
| ▸ | TUBB1 | Q9H4B7 | 7/20 | 1.00 |
| ▸ | POLB | P06746 | 1/20 | 1.00 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 1.00 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ofloxacin SCHEMBL6090650 | 1.00 | KDM4E (1.00) | KDM4ETUBB4ATUBBTUBA3CTUBA1B | |
| Ofloxacin SCHEMBL6092282 | 1.00 | KDM4E (1.00) | KDM4ETUBB4ATUBBTUBA3CTUBA1B | |
| Levofloxacin Anhydrous SCHEMBL1650602 | 1.00 | KDM4E (1.00) | KDM4ETUBB4ATUBBTUBA3CTUBA1B | |
| Levofloxacin Anhydrous SCHEMBL30009030 | 1.00 | KDM4E (1.00) | KDM4ETUBB4ATUBBTUBA3CTUBA1B | |
| Levofloxacin Anhydrous SCHEMBL27810870 | 0.99 | KDM4E (0.98) | KDM4ETUBB4ATUBBTUBA3CTUBA1B | |
| Ofloxacin SCHEMBL9745243 | 0.99 | KDM4E (1.00) | KDM4ETUBB4ATUBBTUBA3CTUBA1B | |
| Dextrofloxacine SCHEMBL4316947 | 0.99 | KDM4E (1.00) | KDM4ETUBB4ATUBBTUBA3CTUBA1B | |
| Ofloxacin SCHEMBL14163982 | 0.99 | KDM4E (1.00) | KDM4ETUBB4ATUBBTUBA3CTUBA1B | |
| Ofloxacin SCHEMBL5532921 | 0.99 | KDM4E (1.00) | KDM4ETUBB4ATUBBTUBA3CTUBA1B | |
| Ofloxacin SCHEMBL24373 | 0.99 | KDM4E (1.00) | KDM4ETUBB4ATUBBTUBA3CTUBA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 171 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119562814-A | Otologic liquid for preventing and/or treating otitis externa and/or otitis media | 西奥利亚制药株式会社 | 2025-03-04 | — | — | CN | claimed |
| WO-2023224045-A1 | OTOLOGICAL SOLUTION FOR PREVENTING AND/OR TREATING OTITIS EXTERNA AND/OR OTITIS MEDIA | セオリアファーマ株式会社 | 2023-11-23 | — | — | WO | claimed |
| CN-108310983-B | Preparation and regeneration method of antibacterial and anti-pollution PVDF ultrafiltration membrane | 山西大学 | 2021-02-02 | — | — | CN | claimed |
| US-9603805-B2 | Easily dosable solid preparation | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2017-03-28 | — | — | US | claimed |
| CN-103813807-B | Easily administrable solid preparation | 持田制药株式会社 | 2017-02-08 | — | — | CN | claimed |
| US-20140308359-A1 | EASILY DOSABLE SOLID PREPARATION | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2014-10-16 | — | — | US | claimed |
| EP-2762167-A1 | EASY-TO-TAKE SOLID PREPARATION | Mochida Pharmaceutical Co., Ltd. (JP) | 2014-08-06 | — | — | EP | claimed |
| US-7678903-B2 | Preparation of levofloxacin hemihydrate free of levofloxacin monohydrate by reacting (S)-(-) 9,10-difluoro-3-methyl-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4] benzoxazine-6-carboxylic acid with N-methyl piperazine to yield crude levofloxacin which is suspended in isopropanol, adding water, precipitating | MATRIX LABORATORIES LIMITED (IN) | 2010-03-16 | — | — | US | claimed |
| US-7629458-B2 | Preparation of levofloxacin and hemihydrate thereof | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2009-12-08 | — | — | US | claimed |
| US-20080097095-A1 | Process for the Preparation of Levofloxacin Hemiydrate | MYLAN LABORATORIES LIMITED (IN) | 2008-04-24 | — | — | US | claimed |
| US-20060276463-A1 | Pure levofloxacin hemihydrate and processes for preparation thereof | RANBAXY LABORATORIES LIMITED (IN) | 2006-12-07 | — | — | US | claimed |
| CN-1735620-A | Pure levofloxacin hemihydrate and process for its preparation | RANBAXY LAB LTD (IN) | 2006-02-15 | — | — | CN | claimed |
| WO-2004055025-A1 | PURE LEVOFLOXACIN HEMIHYDRATE AND PROCESSES FOR PREPARATION THEREOF | RANBAXY LABORATORIES LIMITED (IN) | 2004-07-01 | — | — | WO | claimed |
| EP-0444678-B1 | Process for selectively producing hydrate crystals | DAIICHI SEIYAKU CO (JP) | 1997-09-03 | — | — | EP | claimed |
| US-5545737-A | Process for selectively producing an (S)-9-fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7h-pyrido (1,2,3, -de) (1,4) benzoxazine-6-carboxylic acid hemihydrate or monohydrate | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1996-08-13 | — | — | US | claimed |
| EP-0444678-A1 | Process for selectively producing hydrate crystals | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1991-09-04 | — | — | EP | claimed |
| EP-4039257-B1 | PHARMACEUTICAL COMPOSITION AND KIT CONTAINING A PENAM DERIVATIVE OR SALT THEREOF AND ONE OR MORE COMPOUNDS SELECTED FROM BETA-LACTAMASE INHIBITOR COMPOUND, ANTIBACTERIAL COMPOUND AND SALTS OF THESE | FUJIFILM CORP (JP) | 2026-05-27 | — | — | EP | disclosed |
| US-20260091082-A1 | CYCLIC PEPTIDE DERIVATIVE COMPOSITION FOR TREATING OR PREVENTING EYE DISEASE | DKS CO. LTD. (JP) | 2026-04-02 | — | — | US | disclosed |
| US-5023257-A | Related to ciprofloxacin, in the form of oily suspension; bacterial infections | BAYER AKTIENGESELLSCHAFT (DE) | 1991-06-11 | — | — | US | disclosed |
| EP-0394553-A2 | Use of fluorine containing pyridone carboxylic acid derivatives for preparing a medicament for the treatment of HIV infections | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1990-10-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276463-A1 | Pure levofloxacin hemihydrate and processes for preparation thereof | CYP4F3, QARS1, CYP4F11 | KDM4E 942/4885TUBB4A 1662/4885TUBB 1745/4885 |
| US-20260091082-A1 | CYCLIC PEPTIDE DERIVATIVE COMPOSITION FOR TREATING OR PREVENTING EYE DISEASE | ADCY3, GLP1R, PDE6C | KDM4E 4379/4885TUBB4A 4786/4885TUBB 4710/4885 |
| US-20080097095-A1 | Process for the Preparation of Levofloxacin Hemiydrate | CYP4F3, HPD, CYP4F11 | KDM4E 645/4885TUBB4A 2364/4885TUBB 2337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.